This observational study is looking at new ways to detect heart transplant rejection. Currently, doctors use biopsies (taking a small tissue sample) to check for rejection, but this can be imprecise. This study aims to see how well two newer diagnostic tests, Prospera and HLA antibody testing, compare to a more advanced biopsy analysis called MMDx. Prospera measures donor-derived cell-free DNA (DD-cfDNA) in your blood, which are tiny pieces of DNA from the transplanted heart. HLA antibody testing also uses a blood sample to look for specific antibodies. The study will enroll about 300 heart transplant recipients who are already having a biopsy for medical reasons. The main goal is to see how well the Prospera test can identify T cell-mediated rejection, antibody-mediated rejection, and heart injury, compared to the MMDx results, over 18 months.

Study design

This is an observational study with an unclear status, planning to enroll 300 participants. It is not a randomized trial.

What's involved

Participants will undergo standard of care biopsies and blood tests for Prospera and HLA antibody measurements.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints for this study are measured at 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.